Our customers often face complex content problems that hinder their efficiency, scalability, and customer satisfaction. These challenges cost the enterprise money, time, and risk.
AI is completely disrupting how organizations need to think about their content, whether it is customer-facing or internal. The data reveals just how profound—and significant–this disruption has become
I was recently playing 20 Questions with my good friend John when it occurred to me that it has a lot in common with taxonomy—and, by extension, a solid content strategy.
Did you know that one of the best things you can do for your customers is to create less content?I know what you’re thinking. “Why is Content Rules, a company that has been creating excellent content for our customers for over 30 years, telling me to create less content?”
Content automation is the practice of using systems to perform repetitive tasks to create content; such as formatting, data retrieval, and document assembly. Content automation in the pharmaceutical industry is often implemented for the following reasons:
Artificial intelligence (AI) used to be something we thought about as a future need or threat. Just a couple of years ago, the impact of AI on our daily lives was indirect. Companies employed AI systems that ran behind a user interface. Even though we have interacted with AI for